120362-26-7

Basic information

• Product Name: ethyl 1-ribofuranosyl-1,2,4-triazole-3-carboximidate
• Synonyms: ethyl 1-ribofuranosyl-1,2,4-triazole-3-carboximidate
• CAS NO: 120362-26-7
• Molecular Formula: C10H16 N4 O5
• Molecular Weight: 0
• Mol File: 120362-26-7.mol

Chemical Properties

• Boiling Point: 527.5°Cat760mmHg
• Flash Point: 272.8°C
• Appearance: /
• Density: 1.72g/cm³
• Vapor Pressure: 5.89E-12mmHg at 25°C
• Refractive Index: 1.696
• CAS DataBase Reference: ethyl 1-ribofuranosyl-1,2,4-triazole-3-carboximidate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 1-ribofuranosyl-1,2,4-triazole-3-carboximidate(120362-26-7)
• EPA Substance Registry System: ethyl 1-ribofuranosyl-1,2,4-triazole-3-carboximidate(120362-26-7)

Safety Data

• Hazardous Substances Data: 120362-26-7(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H16N4O5/c1-2-18-8(11)9-12-4-14(13-9)10-7(17)6(16)5(3-15)19-10/h4-7,10-11,15-17H,2-3H2,1H3/b11-8-/t5-,6-,7-,10-/m1/s1

Upstream product

• 40371-99-1 3-cyano-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-1,2,4-triazole 
• 36791-04-5 ribavirin 
• 40372-03-0 2',3',5'-Tri-O-acetyl-1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide 
• 141-52-6 sodium ethanolate 

Relevant articles and documents

Synthesis and anti-leukemic activity of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates

A novel class of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates of the formula: STR1 wherein R1 is methyl or ethyl and R2 is β-D-ribofuranosyl, are useful as anti-leukemic agents.

Synthesis and antitumor activity of ribavirin imidates. A new facile synthesis of ribavirin amidine (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride)

Methyl 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboximidate (4) and ethyl 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboximidate (6) were synthesized and tested for antitumor and antiviral activity. A new facile synthesis of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride (5), starting with imidate 4, was also developed. The imidates 4 and 6 differed greatly in solubility and dosing requirements. Even so, both compounds exhibited significant activity in vivo against murine leukemia L1210. Nontoxic dosing with 4 also significantly diminished Friend leukemia induced splenomegaly. In contrast, neither imidate was active in vitro.